Clinical trials: Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA)
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
The study is being conducted to evaluate the absorption, metabolism and excretion of [14C]SHR0302 in healthy Chinese adult male subjects.
- Trial name
- NCT05047341
- Testing
- SHR0302、[14C]SHR0302
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
RA - Rheumatoid Arthritis
Pentacam Study of the Cornea in RA Patients
To evaluate the effect of rheumatoid arthritis (RA) activity on the corneal densitometry, corneal curvature (CC), central corneal thickness (CCT), and lens densitometry by Pentacam and compared these parameters with those of…
- Trial name
- NCT05241639
- Testing
- Pentacam
- Where
- 2 sites in Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Minia University
Rheumatoid Arthritis (RA)
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including…
- Trial name
- NCT02955212
- Testing
- Upadacitinib
- Where
- 43 sites in Brazil, China and 1 more
- Volunteers
- 338 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT03823378
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 30 sites in Belgium, Canada and 5 more
- Volunteers
- 97 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.
- Trial name
- NCT03823391
- Testing
- ABBV-3373, Adalimumab
- Where
- 30 sites in United States, Germany and 5 more
- Volunteers
- 48 people
- Sponsor
- AbbVie
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)…
- Trial name
- NCT03682705
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 115 sites in United States, Belgium and 7 more
- Volunteers
- 242 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA), Crohn's Disease (CD)
UCB Cimzia Pregnancy Follow-up Study
The purpose of this observational follow-up study is to collect data systematically on pregnancies and offspring of women who become pregnant while participating in a Certolizumab Pegol (CZP) study or whose pregnancies have…
- Conditions
- Rheumatoid Arthritis (RA), Crohn's Disease (CD), Psoriatic Arthritis (PsA), Axial Spondyloarthritis and Ankylosing Spondylitis
- Trial name
- NCT02775656
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis(RA)
A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX
To demonstrate that SM03 added to methotrexate (MTX) reduce signs and symptoms of rheumatoid arthritis (RA) in Chinese RA participants with an inadequate response to MTX.
- Trial name
- NCT04312815
- Testing
- SM03, MTX
- Where
- China
- Volunteers
- 510 people
- Sponsor
- SinoMab BioScience Ltd
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROCID-DCH (NCT03456206)
- Testing
- Intake of red and processed meat and fibres, Lifestyle factors independently or combined
- Where
- Denmark
- Volunteers
- 57,053 people
- Sponsor
- University of Southern Denmark
Rheumatoid Arthritis (RA)
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
An Agency for Healthcare Research and Quality executive summary indicated that better comparative effectiveness trial designs are needed to determine the relative merits of existing versus new and expensive biologic drug…
- Trial name
- MAZERATI (NCT02353780)
- Testing
- TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dr. Larry W. Moreland
Crohn's Disease, Ulcerative Colitis (UC)
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.
- Conditions
- Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis
- Trial name
- IMPROVE (NCT03223012)
- Where
- 15 sites in Portugal
- Volunteers
- 116 people
- Sponsor
- AbbVie
RA - Rheumatoid Arthritis
Evaluating the Role of Intra-articular Injections of Platelet Rich Plasma (PRP) in Patients With Rheumatoid Arthritis.
To evaluate the therapeutic effect of 3 local doses of PRP intra-articular injection in patients with RA regarding the improvement of disease activity and quality of life versus placebo.
- Trial name
- NCT04264494
- Testing
- PRP intra articular injection, NACL intra articular injection
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Dalia Salah Saif
Rheumatoid Arthritis (RA)
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
The purpose of this study is to assess the safety and efficacy of MK-8457 + Methotrexate (MTX) in participants with active rheumatoid arthritis (RA) despite MTX therapy.
- Trial name
- NCT01569152
- Testing
- MK-8457 100 mg, Methotrexate
- Volunteers
- 82 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis (RA), Spondyloarthritis (SpA)
Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics
Background : Inflammatory arthritis (rheumatoid arthritis (RA) or spondyloarthritis (SpA) are painful chronic diseases which impair quality of life and work capacity. Biologics are very effective and widely used therapies.
- Trial name
- BIOSAFE (NCT02855320)
- Testing
- Nurse-led self-management education intervention
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis (RA)
Masitinib in Refractory Active Rheumatoid Arthritis
The objective is to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day to methotrexate, with a randomisation 1:1:1, in treatment of patients with active rheumatoid arthritis with inadequate response to 1.
- Trial name
- NCT01410695
- Testing
- masitinib 3 mg, masitinib 6.0 mg, methotrexate
- Where
- Czechia
- Volunteers
- 324 people
- Sponsor
- AB Science
Rheumatoid Arthritis (RA)
Niclosamide With Etanercept in Rheumatoid Arthritis
Assessment of the adjuvant use Niclosamide With Etanercept in Rheumatoid Arthritis
- Trial name
- NCT03160001
- Testing
- Niclosamide, Etanercept
- Where
- Iraq
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Faiq Gorial
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents
The rationale for this study is to further explore if development of antibodies against TNF-α blocking agents is associated with reduced clinical effect/worsened clinical outcome.
- Trial name
- NCT01691014
- Testing
- non-interventional study
- Where
- 13 sites in Denmark
- Volunteers
- 79 people
- Sponsor
- Pfizer